Adriana Antohe, MD

18/11/2025

12/11/2025

FRESHAIR4Life, derulat în România de Grupul RespiRO - Centrul Național de Studii pentru Medicina Familiei, nu este un proiect obișnuit. Este un program care construiește capacitate în cercetarea implementării intervențiilor considerate eficace din paleta Best Buys a Organizației Mondiale a Sănătății (OMS).
👩‍⚕️👨‍🏫 Medici de familie, specialiști în sănătate publică, pneumologi și psihologi testează, împreună cu elevi și profesori, aplicabilitatea, eficacitatea și impactul unor materiale educaționale dezvoltate internațional și adaptate local.
🎯 Miza? Crearea unui pachet educațional complet, pentru prevenirea initierii fumatului, ușor de implementat în școli din toată țara — nu doar pentru liceeni, ci și pentru elevii din ciclul gimnazial.
🙏 Suntem recunoscători profesorilor și elevilor din cele 7 licee brașovene pentru participarea lor activă la cercetare — prin completarea chestionarelor, acceptul de a se implica în interviuri și focus grupurile viitoare.
🎩 Jos pălăria! pentru că nu stați deoparte, ci contribuiți direct la construirea unui viitor mai sănătos pentru tineri.


Află mai multe: https://www.ipcrg.org/freshair4life

30/10/2025

Multumim, Domnule Profesor Craiu Mihai 🙏

15/10/2025

Ce boli se încadrează la handicap în 2025 și care sunt pașii pentru obținerea certificatului de la DGASPC

14/10/2025

11/10/2025

⌛ Behind every to***co statistic is a future at risk. For the first time, WHO’s global ***co trends report assessed e-cigarette use worldwide. And for Europe’s future, it is one of the greatest risks:
⚠️ Among adolescents aged 13–15, 14.3% use e-cigarettes – the highest rate in the world!
⚠️They are up to 3 times more likely to use e-cigarettes than adults, with girls showing especially high rates.
⚠️ Europe also reports the world’s highest adolescent cigarette smoking rate (8.4%), with girls slightly ahead of boys.

To***co industry marketing tactics – flavours, bright packaging, social media promotion – are hooking a new generation on ****ne.

Protecting children from to***co and ni****ne products is urgent. Every loophole exploited by the industry is another pathway to addiction.

But evidence-based policy actions such as WHO/Europe quick buys can tackle this challenge.

Learn more: https://www.who.int/europe/news/item/08-10-2025-who-european-region-has-the-highest-rate-of-to***co-use-in-the-world--with-an-alarming-rise-in-young-people-using-e-cigarettes--global-report-warns/

***coExposed ***coTrends

10/10/2025

07/10/2025

Clinical trial shows an allergy spray helps prevent COVID.

Scientists in Germany tested azelastine, a decades-old antihistamine spray usually prescribed for hay fever and dust allergies, to see if it could prevent viral infections.

In a clinical trial of 450 healthy adults, nearly all vaccinated, participants sprayed either azelastine or a placebo into their noses three times a day for eight weeks. The results were striking: only 2.2 percent of the azelastine group caught COVID-19, compared with 6.7 percent in the placebo group – a threefold difference.

And when infections did occur, they cleared faster: just over three days versus more than five.

Even more interesting, people using the spray were also less likely to catch other seasonal viruses like influenza or rhinovirus, and when they did, symptoms resolved more quickly.

Researchers think azelastine may interfere with how viruses attach to human cells in the nose, where many infections begin.

To be clear, this was a relatively small study, and azelastine is not approved by the FDA to prevent infections. Vaccines, masks in crowded spaces, and staying home when sick remain the best protections.

But the findings suggest that a cheap, over-the-counter spray – one already sitting on pharmacy shelves – could someday become an unexpected tool in reducing the spread of COVID-19 and other respiratory viruses.

Read the study:
"Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial." JAMA, 2 Sep 2025.